// App-Quantinova.ai

POS0185 (2022) : BELIMUMAB DISRUPTS MEMORY B-CELL TRAFFICKING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Researchers

Presenter

  • E. J. Arends

Principal Investigators

  • M. Zlei

  • C. M. Tipton

  • J. Cotic

  • Z. Osmani

  • F. de Bie

  • S. Kamerling

  • A. van Maurik

  • R. Dimelow

  • Y. I. Gregan

  • N. L. Fox

  • T. Rabelink

  • D. Roth

  • I. Sanz

  • J. J. M. van Dongen

  • C. van Kooten

  • Y. K. O. Teng

Medical Centers

  • Leiden University Medical Center, Department of Orthopaedic Surgery, Leiden, Netherlands

  • Leiden University Medical Center, Department of Immunology, Leiden, Netherlands

  • Lowance Center for Human Immunology, Emory University, Department of Medicine, Division of Rheumatology, Atlanta, United States of America

  • GlazoSmithKline, Clinical Statistics, Brentforf, United Kingdom

  • GlaxoSmithKline, Clinical Biomarker Group, Stevenage, United Kingdom

  • GlaxoSmithKline, Clinical Pharmacology Modelling and Simulation, Stevenage, United Kingdom

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, United States of America

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, United States of America

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, United States of America

Locations

  • Netherlands

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Belimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • N/A

Study Id's

  • NCT00071487

  • NCT00410384

  • NCT01632241

  • NCT01649765

  • NCT03747159

  • NCT03312907

Sponsors

  • GSK

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved